Literature DB >> 24890762

A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab.

P Jayasekera1, R Parslew, A Al-Sharqi.   

Abstract

Rituximab, a chimeric B-cell-depleting monoclonal antibody, is a well-established therapy for rheumatoid arthritis. It is emerging that classical psoriatic lesions and plantar pustular psoriasis (PPP) are cutaneous side-effects of this drug. Antitumour necrosis factor (anti-TNF) therapies have multiple documented side-effects including PPP and psoriasis. We report a patient who has rheumatoid arthritis, who failed on anti-TNF therapies and then was commenced on rituximab. Subsequently she developed localized PPP. Due to deterioration of her joint disease she was switched to the interleukin-6 blocker tocilizumab, and the PPP resolved.
© 2014 British Association of Dermatologists.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24890762     DOI： 10.1111/bjd.13146

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


  8 in total

Review 1.  Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness.

Authors:  Ya-Chu Tsai; Tsen-Fang Tsai
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-11-06       Impact factor: 5.346

Review 2.  Cutaneous Manifestations of Reactions to Biologics.

Authors:  Iris M Otani; Amy S Levin; Aleena Banerji
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-21       Impact factor: 4.806

3.  Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions.

Authors:  Shoko Mori; Alanna Hickey; Stephen W Dusza; Mario E Lacouture; Alina Markova
Journal:  J Am Acad Dermatol       Date:  2018-10-26       Impact factor: 11.527

Review 4.  B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.

Authors:  Mathieu Uzzan; Jean-Frederic Colombel; Andrea Cerutti; Xavier Treton; Saurabh Mehandru
Journal:  Dig Dis Sci       Date:  2016-09-21       Impact factor: 3.199

5.  E3 ubiquitin ligase NEDD4L negatively regulates keratinocyte hyperplasia by promoting GP130 degradation.

Authors:  Huan Liu; Wenlong Lin; Zhiyong Liu; Yinjing Song; Hao Cheng; Huazhang An; Xiaojian Wang
Journal:  EMBO Rep       Date:  2021-03-26       Impact factor: 8.807

6.  Relevance of Inflammatory Cytokine mRNA Expression of Tumour Necrosis Factor- Alpha (TNF α), Interleukin 17A (IL 17A) and Interleukin 6 (IL 6) in Indian Patients with Psoriasis.

Authors:  Saiqa R Shah; Sadiya B Shaikh; Yashodhar P Bhandary; Shaheena Yassir; Manjunath M Shenoy
Journal:  Indian Dermatol Online J       Date:  2022-03-03

7.  Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab.

Authors:  Hana S Alahmari; Nasser Y Alhowaish; Mohammed A Omair
Journal:  Case Rep Rheumatol       Date:  2019-10-17

Review 8.  Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease.

Authors:  Marko Kumric; Piero Marin Zivkovic; Tina Ticinovic Kurir; Josip Vrdoljak; Marino Vilovic; Dinko Martinovic; Andre Bratanic; Ivan Kresimir Lizatovic; Josko Bozic
Journal:  Diagnostics (Basel)       Date:  2021-12-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.